{"pmid":32392389,"title":"COVID-19 in Patients with Myasthenia Gravis.","text":["COVID-19 in Patients with Myasthenia Gravis.","INTRODUCTION: Coronavirus Disease 2019 (COVID-19) has rapidly become a global pandemic, but little is known about potential impact on patients with myasthenia gravis (MG). METHODS: We studied the clinical course of COVID-19 in 5 hospitalized patients with autoimmune MG (4 with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies). RESULTS: Two patients required intubation for hypoxemic respiratory failure, while one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID-19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications. DISCUSSION: Our findings suggest that the clinical course and outcomes in patients with MG and COVID-19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population. This article is protected by copyright. All rights reserved.","Muscle Nerve","Anand, Pria","Slama, Michael C C","Kaku, Michelle","Ong, Charlene","Cervantes-Arslanian, Anna M","Zhou, Lan","David, William S","Guidon, Amanda C","32392389"],"abstract":["INTRODUCTION: Coronavirus Disease 2019 (COVID-19) has rapidly become a global pandemic, but little is known about potential impact on patients with myasthenia gravis (MG). METHODS: We studied the clinical course of COVID-19 in 5 hospitalized patients with autoimmune MG (4 with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies). RESULTS: Two patients required intubation for hypoxemic respiratory failure, while one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID-19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications. DISCUSSION: Our findings suggest that the clinical course and outcomes in patients with MG and COVID-19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population. This article is protected by copyright. All rights reserved."],"journal":"Muscle Nerve","authors":["Anand, Pria","Slama, Michael C C","Kaku, Michelle","Ong, Charlene","Cervantes-Arslanian, Anna M","Zhou, Lan","David, William S","Guidon, Amanda C"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392389","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/mus.26918","keywords":["covid-19","immunosuppression","myasthenia gravis","neuroimmunology","neuromuscular disorders"],"topics":["Treatment"],"weight":1,"_version_":1666528580114317312,"score":9.490897,"similar":[{"pmid":32503877,"title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","text":["Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.","Sci Immunol","Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H","32503877"],"abstract":["Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial."],"journal":"Sci Immunol","authors":["Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503877","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1126/sciimmunol.abd0110","locations":["Bruton"],"e_drugs":["acalabrutinib"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488360787968,"score":145.89441},{"pmid":32314799,"title":"Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","text":["Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R","32314799"],"abstract":["Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314799","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25907","keywords":["coronavirus","disease control","immune responses","immunodulators","interleukin","virus classification"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138493493968898,"score":139.1781},{"pmid":32376398,"title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.","text":["Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.","A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8mg/kg by two consecutive intravenous infusions 12h apart. A third infusion was optional based on clinical response. The outcome measure was an improvement in ARDS assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24-72h and 10days after tocilizumab administration. Out of 100 treated patients (88M, 12F; median age: 62years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0-2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS>/=7 before TCZ). Overall at 10days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and interleukin 6 (IL-6) indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement.","Autoimmun Rev","Toniati, Paola","Piva, Simone","Cattalini, Marco","Garrafa, Emirena","Regola, Francesca","Castelli, Francesco","Franceschini, Franco","Foca, Emanuele","Andreoli, Laura","Latronico, Nicola","32376398"],"abstract":["A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8mg/kg by two consecutive intravenous infusions 12h apart. A third infusion was optional based on clinical response. The outcome measure was an improvement in ARDS assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24-72h and 10days after tocilizumab administration. Out of 100 treated patients (88M, 12F; median age: 62years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0-2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS>/=7 before TCZ). Overall at 10days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and interleukin 6 (IL-6) indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement."],"journal":"Autoimmun Rev","authors":["Toniati, Paola","Piva, Simone","Cattalini, Marco","Garrafa, Emirena","Regola, Francesca","Castelli, Francesco","Franceschini, Franco","Foca, Emanuele","Andreoli, Laura","Latronico, Nicola"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376398","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102568","locations":["Brescia","Italy","Brescia","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666262687630229504,"score":132.18388},{"pmid":32448770,"title":"Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.","text":["Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.","BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days. RESULTS: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p<0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). CONCLUSION: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug.","Eur J Intern Med","Morena, Valentina","Milazzo, Laura","Oreni, Letizia","Bestetti, Giovanna","Fossali, Tommaso","Bassoli, Cinzia","Torre, Alessandro","Cossu, Maria Vittoria","Minari, Caterina","Ballone, Elisabetta","Perotti, Andrea","Mileto, Davide","Niero, Fosca","Merli, Stefania","Foschi, Antonella","Vimercati, Stefania","Rizzardini, Giuliano","Sollima, Salvatore","Bradanini, Lucia","Galimberti, Laura","Colombo, Riccardo","Micheli, Valeria","Negri, Cristina","Ridolfo, Anna Lisa","Meroni, Luca","Galli, Massimo","Antinori, Spinello","Corbellino, Mario","32448770"],"abstract":["BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days. RESULTS: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p<0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). CONCLUSION: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug."],"journal":"Eur J Intern Med","authors":["Morena, Valentina","Milazzo, Laura","Oreni, Letizia","Bestetti, Giovanna","Fossali, Tommaso","Bassoli, Cinzia","Torre, Alessandro","Cossu, Maria Vittoria","Minari, Caterina","Ballone, Elisabetta","Perotti, Andrea","Mileto, Davide","Niero, Fosca","Merli, Stefania","Foschi, Antonella","Vimercati, Stefania","Rizzardini, Giuliano","Sollima, Salvatore","Bradanini, Lucia","Galimberti, Laura","Colombo, Riccardo","Micheli, Valeria","Negri, Cristina","Ridolfo, Anna Lisa","Meroni, Luca","Galli, Massimo","Antinori, Spinello","Corbellino, Mario"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448770","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ejim.2020.05.011","keywords":["covid-19","il-6 inhibitors","tocilizumab"],"locations":["thrombocytopenia","Milan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1667785214012686336,"score":131.85057},{"pmid":32317557,"title":"Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.","text":["Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.","As COVID-19 cases surge worldwide, an urgent need exists to enhance our understanding of the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapy. The purpose of this manuscript is to review our initial clinical experience in 32 patients with confirmed COVID-19 treated with ECMO.A multi-institutional registry and database was created and utilized to assess all patients who were supported with ECMO provided by SpecialtyCare. Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, specific medications utilized to treat COVID-19, and short-term outcomes through hospital discharge. This analysis includes all of our patients with COVID-19 supported with ECMO, with an analytic window starting March 17, 2020 when our first COVID-19 patient was placed on ECMO, and ending April 9, 2020.During the 24 days of this study, 32 consecutive patients with COVID-19 were placed on ECMO at 9 different hospitals. As of the time of analysis, 17 remain on ECMO, 10 died prior to or shortly after decannulation, and 5 are alive and extubated after removal from ECMO, with one of these 5 discharged from the hospital. Adjunctive medication in the surviving patients while on ECMO was as follows: 4 of 5 survivors received intravenous steroids, 3 of 5 survivors received antiviral medications (Remdesivir), 2 of 5 survivors were treated with anti-interleukin-6-receptor monoclonal antibodies (Tocilizumab or Sarilumab), and 1 of 5 survivors received hydroxychloroquine.An analysis of 32 COVID-19 patients with severe pulmonary compromise supported with ECMO suggests that ECMO may play a useful role in salvaging select critically ill patients with COVID-19. Additional patient experience and associated clinical and laboratory data must be obtained to further define the optimal role of ECMO in patients with COVID-19 and ARDS. These initial data may provide useful information to help define the best strategies to care for these challenging patients, and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19.","ASAIO J","Jacobs, Jeffrey P","Stammers, Alfred H","St Louis, James","Hayanga, J W Awori","Firstenberg, Michael S","Mongero, Linda B","Tesdahl, Eric A","Rajagopal, Keshava","Cheema, Faisal H","Coley, Tom","Badhwar, Vinay","Sestokas, Anthony K","Slepian, Marvin J","32317557"],"abstract":["As COVID-19 cases surge worldwide, an urgent need exists to enhance our understanding of the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapy. The purpose of this manuscript is to review our initial clinical experience in 32 patients with confirmed COVID-19 treated with ECMO.A multi-institutional registry and database was created and utilized to assess all patients who were supported with ECMO provided by SpecialtyCare. Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, specific medications utilized to treat COVID-19, and short-term outcomes through hospital discharge. This analysis includes all of our patients with COVID-19 supported with ECMO, with an analytic window starting March 17, 2020 when our first COVID-19 patient was placed on ECMO, and ending April 9, 2020.During the 24 days of this study, 32 consecutive patients with COVID-19 were placed on ECMO at 9 different hospitals. As of the time of analysis, 17 remain on ECMO, 10 died prior to or shortly after decannulation, and 5 are alive and extubated after removal from ECMO, with one of these 5 discharged from the hospital. Adjunctive medication in the surviving patients while on ECMO was as follows: 4 of 5 survivors received intravenous steroids, 3 of 5 survivors received antiviral medications (Remdesivir), 2 of 5 survivors were treated with anti-interleukin-6-receptor monoclonal antibodies (Tocilizumab or Sarilumab), and 1 of 5 survivors received hydroxychloroquine.An analysis of 32 COVID-19 patients with severe pulmonary compromise supported with ECMO suggests that ECMO may play a useful role in salvaging select critically ill patients with COVID-19. Additional patient experience and associated clinical and laboratory data must be obtained to further define the optimal role of ECMO in patients with COVID-19 and ARDS. These initial data may provide useful information to help define the best strategies to care for these challenging patients, and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19."],"journal":"ASAIO J","authors":["Jacobs, Jeffrey P","Stammers, Alfred H","St Louis, James","Hayanga, J W Awori","Firstenberg, Michael S","Mongero, Linda B","Tesdahl, Eric A","Rajagopal, Keshava","Cheema, Faisal H","Coley, Tom","Badhwar, Vinay","Sestokas, Anthony K","Slepian, Marvin J"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317557","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1097/MAT.0000000000001185","e_drugs":["remdesivir","Hydroxychloroquine","tocilizumab","sarilumab","Steroids"],"topics":["Treatment"],"weight":1,"_version_":1666138493713121281,"score":129.88426}]}